



PATENTS  
EL 984 914 870 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Bhatti, <i>et al.</i>	:	Examiner:	To be assigned
Serial No.:	10/607,930	:	Art Unit:	1614
Filed:	June 27, 2003	:	Docket No.:	T103 1530.1
For:	N-Aryl Diazaspiracyclic Compounds and Methods of Preparation and Use Thereof			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the additional references listed on the attached Form PTO-1449 to the Commissioner for Patents. Copies of eight (8) references listed on Applicants' form PTO-1449 are enclosed herewith. Each item of information submitted with this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. A copy of the Partial International Search Report citing the references is also enclosed.

Document P1 is an apparent English language equivalent of WO 03 032997 A (in German), as mentioned in the Partial Search Report (D3).

Document F4 is a Japanese language document having an English language abstract which appears to indicate that the document discusses spiro compounds of the indicated formula, asserted to have high affinity for the  $\alpha 7$  nicotinic receptor which are asserted to "provide remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder and so on." Although an Australian application, AU0141056A5, was indicated as a counterpart to this application, no equivalent English specification appears to be readily available at this time.


Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as documents, and/or to prove that the

cited information may not be prior art, and/or to prove that the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that any search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Respectfully submitted,

Date: Dec 17, 2003



Carl B. Massey, Jr.  
Registration No. 44,224  
Attorney for Applicants

**Docket: T103 1530.1**  
Womble Carlyle Sandridge & Rice, PLLC  
Post Office Box 7037  
Atlanta, Georgia 30357-00378  
Telephone (336) 721-3681  
Facsimile (336) 726-8074



## EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number : EL 984 914 870 US

Date of Deposit : December 18, 2003

Type of Documents : Supplemental Information Disclosure  
Statement (2 pages);

Form PTO-1449 (1 page) and References:  
1 US Patent;  
4 Foreign Patents;  
3 Other Documents


Return Postcard

Serial No. : 10/607,930

Filing Date: : June 27, 2003

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

*Diane H. Marshall* (signature)  
Diane H. Marshall



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DKT NO. T103 1530.1		SERIAL NO. 10/607,930	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Bhatti, <i>et al.</i>			
				FILING DATE 06-27-03		GROUP 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
	P1	US 2003/ 0171359A1		Dahmann, <i>et al.</i>			16 Oct. 2002
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL.	TRANSLATION YES NO
	F1	EP 0 970 957 A1	12 Jan 2000				
	F2	GB 2 142 332 A	16 Jan 1985				
	F3	WO 01/30780 A2 and A3	3 May 2001				
	F4	WO 01/66546 A1	13 Sept. 2001				
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)							
	D1	Mukund, M. M., <i>et al.</i> , "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decenes," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 12(7): 1103-1107 (2002).					
	D2	Smyth, M.S., <i>et al.</i> , "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 1: Design of Potent and Specific 3,9-Diazaspiro [5.5]undecanes," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 11(10): 1289-1292 (2001).					
	D3	PARTIAL INTERNATIONAL SEARCH REPORT (7 November 2003).					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							